516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+ tumors

516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+ tumors

Bibliographic Details
Main Authors:	Xinhua Wang, Lei Shi, Oi Kwan Wong, Qi Fei, Leonard Post, Xiaocheng Chen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
by: Yan Yang, et al.
Published: (2021-07-01)

A Novel Anti-B7-H3 × Anti-CD3 Bispecific Antibody with Potent Antitumor Activity
by: Yan Feng, et al.
Published: (2022-01-01)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
by: Martina S. Lutz, et al.
Published: (2023-04-01)

1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01)

The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas
by: Samuel J. Holzmayer, et al.
Published: (2024-05-01)

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
by: Xavier Chauchet, et al.
Published: (2022-05-01)

Targum Onkelos til Genesis 4,7B
by: Bjørn Kvam
Published: (1995-09-01)

B7-H3/CD276: An Emerging Cancer Immunotherapy
by: Wu-Tong Zhou, et al.
Published: (2021-07-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

CD47-Blocking Antibodies and Atherosclerosis
by: John J. Ryan, MD
Published: (2016-08-01)

Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach
by: Punchita Rujirachaivej, et al.
Published: (2025-01-01)

MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody
by: Hongjian Li, et al.
Published: (2020-08-01)

Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
by: Yuan He, et al.
Published: (2019-02-01)

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
by: Grandclément, C, et al.
Published: (2024)

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
by: C. Grandclément, et al.
Published: (2024-03-01)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
by: Yun Yang, et al.
Published: (2023-12-01)

CD47 is highly expressed in gliomas and targeting CD47 is a promising therapeutic strategy
by: Jiaying Yang, et al.
Published: (2021-03-01)

Synthesis and Characterization of Some Bis-1,3 Oxazepine - 4,7- dione and 1, 3 – Diazepine -4,7- dione Derivatives
by: Saad Salim Jasim
Published: (2018-06-01)

On the diophantine equation x² + 4.7ᵇ = y²ʳ
by: Yow, Kai Siong, et al.
Published: (2013)

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody
by: Xianglei Liu, et al.
Published: (2021-12-01)

Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia.
by: Ya-Lan Guo, et al.
Published: (2009-01-01)

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?
by: Renee Bouwstra, et al.
Published: (2019-05-01)

Blocking ANGPTL3 and CD47 impact on atherosclerosis-correspondence
by: Han-Yong Hou, et al.
Published: (2025-02-01)

IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
by: Chunmei Yang, et al.
Published: (2024-11-01)

Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery
by: Artem S. Grevtsev, et al.
Published: (2023-12-01)

Role of CD47 in Hematological Malignancies
by: Entsar Eladl, et al.
Published: (2020-07-01)

Targeting CD47 for cancer immunotherapy
by: Zhongxing Jiang, et al.
Published: (2021-10-01)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
by: C. Grandclement, et al.
Published: (2022-06-01)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
by: Betancur, Paola A., et al.
Published: (2017)

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
by: Paola A. Betancur, et al.
Published: (2017-04-01)

630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models
by: Peter Lamb, et al.
Published: (2020-11-01)

4,7-Dimethoxy-6-propyl-2<i>H</i>-1,3-benzodioxole-5-carbaldehyde
by: Dmitry V. Tsyganov, et al.
Published: (2023-06-01)

B7-H3/CD276 and small-cell lung cancer: What's new?
by: Federico Pio Fabrizio, et al.
Published: (2024-01-01)

917 A novel B7H3×4–1BB bispecific antibody for solid tumor treatment
by: Qun Zhao, et al.
Published: (2023-11-01)

Facilitating cholangiocarcinoma inhibition by targeting CD47
by: Kulthida Vaeteewoottacharn, et al.
Published: (2024-12-01)

Deciphering the role of CD47 in cancer immunotherapy
by: Yu'e Liu, et al.
Published: (2024-09-01)

Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond
by: Amber Afzal, et al.
Published: (2024-07-01)

Structural–functional diversity of CD47 proteoforms
by: Ting Zhang, et al.
Published: (2024-02-01)

The role of CD47 in non-neoplastic diseases
by: Chao Wang, et al.
Published: (2023-12-01)